HER2-Positive Metastatic Breast Cancer: Current Status and Promising Agents on the Horizon

Download All
Review the latest data and expert guidance to enhance treatment of your patients with HER2-positive MBC! This comprehensive program features a text-based educational module with downloadable slides and focused clinical commentaries on recent advances and emerging research.
Neelima Denduluri, MD, FASCO
Heather McArthur, MD, MPH


Are you prepared to use trastuzumab deruxtecan and tucatinib for your patients with HER2+ MBC and disease progression on standard-of-care HER2-targeted therapies?

Heather McArthur, MD, MPH Released: January 21, 2020

Up to one half of patients with HER2+ MBC will develop brain metastases in the course of their disease. Read my thoughts on how I approach management of this challenging disease manifestation, including integration of recently approved HER2-targeted agents.

Neelima Denduluri, MD, FASCO Released: April 29, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Puma Biotechnology, Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings